Treatment news for COVID 19

MHRA have approved the oral antiviral Lageviro (molnuupiravir) for treating COVID 19 stating that the antiviral is safe and effective at reducing the risk of hospitalisation and death in people with mild to moderate COVID-19 who are at increased risk of developing severe disease. Such risk factors include obesity, older age (>60 years), diabetes mellitus, or heart disease. The government and the NHS will confirm how this COVID-19 treatment will be deployed to patients in due course.

First oral antiviral for COVID-19, Lagevrio (molnupiravir), approved by MHRA - GOV.UK (www.gov.uk)